Barbara Calamini
Senior Director Eli Lilly & Co.
Seminars
Thursday 20th August 2026
Clinical Evaluation of Oligo Therapeutic for Parkinson’s Disease: Insights into Target Engagement, Dose Escalation & Safety
2:30 pm
- Examining emerging clinical data from Parkinson’s oligonucleotide program, highlighting evidence of CSF-based target engagement, protein reduction, and safety profile
- Exploring findings from higher dose cohorts and longitudinal patient follow-ups, providing insight into dose-response relationships
- How these clinical results inform next steps in development, including potency threshold considerations, patient cohort selection, and clinical strategy
